Leap Therapeutics Inc
LPTX
查看详细走势图
2.050USD
0.000
收盘 12/19, 16:00（美东）报价延迟15分钟
84.95M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
0.00%
5天
0.00%
1月
0.00%
6月
+443.77%
今年开始到现在
-28.70%
1年
-29.55%
查看详细走势图
TradingKey Leap Therapeutics Inc股票评分
单位: USD 更新时间: 2025-11-12操作建议
Leap Therapeutics Inc当前公司基本面数据相对非常健康，当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价max_target_price。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Leap Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
3.000
目标均价
+669.23%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Leap Therapeutics Inc亮点
亮点风险
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-1.68，处于3年历史低位
机构减仓
最新机构持股9.06M股，环比减少56.49%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值1.16M
活跃度增加
近期活跃度增加，过去20天平均换手率1.51
Leap Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Leap Therapeutics Inc简介
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
公司代码LPTX
公司Leap Therapeutics Inc
CEOOnsi (Douglas E)
网址https://www.leaptx.com/
常见问题
Leap Therapeutics Inc(LPTX)的当前股价是多少？
Leap Therapeutics Inc(LPTX)的当前股价是 2.050。
Leap Therapeutics Inc的股票代码是什么？
Leap Therapeutics Inc的股票代码是LPTX。
Leap Therapeutics Inc股票的52周最高点是多少？
Leap Therapeutics Inc股票的52周最高点是3.610。
Leap Therapeutics Inc股票的52周最低点是多少？
Leap Therapeutics Inc股票的52周最低点是0.222。
Leap Therapeutics Inc的市值是多少？
Leap Therapeutics Inc的市值是84.95M。
Leap Therapeutics Inc的净利润是多少？
Leap Therapeutics Inc的净利润为-67.79M。
现在Leap Therapeutics Inc(LPTX)的股票是买入、持有还是卖出？
根据分析师评级，Leap Therapeutics Inc(LPTX)的总体评级为--，目标价格为3.000。
Leap Therapeutics Inc(LPTX)股票的每股收益（EPS TTM）是多少
Leap Therapeutics Inc(LPTX)股票的每股收益（EPS TTM）是-1.218。
相关品种
